Share Twitter LinkedIn Facebook Email Ghassan Abou-Alfa, MD, MBA, explains the shortcomings of the RECIST study in measuring efficacy in hepatocellular carcinoma (HCC) patients at Annual Meeting 2018.
Edetek’s CONFORM Platform: Streamlining Clinical Data Management in Oncology Trials General 3 Mins Read
High-Dose Chemotherapy for Recurrent Germ Cell Tumors: ASCO 2024 Study Results – Hedyeh Ebrahimi, MD – City of Hope ASCO Annual Meeting 2 Mins Read
